Navigation Links
AspenBio Pharma to Present at the Roth Capital Partners 20th Annual Growth Stock Conference

CASTLE ROCK, Colo., Feb. 14 /PRNewswire-FirstCall/ -- AspenBio Pharma, Inc. (Nasdaq: APPY) an emerging bio-pharmaceutical company dedicated to the development of novel drugs and diagnostics for animals and humans, has been invited to present at the 20th Annual Roth Capital Partners Growth Stock Conference. The conference will be held February 18-21, 2008 at the Ritz Carlton Laguna Niguel in Dana Point, California.

Roth Capital Partners Stock Conferences are one of the largest in the nation for micro and small-cap companies in technology, healthcare, financial services and consumer products sectors. More than 1,000 institutional investors are expected to attend.

AspenBio's president and CEO, Richard Donnelly, is scheduled to present on Tuesday, February 19 at 3:00 PM Pacific Time (6:00 PM Eastern Time), followed by a break out session and one-on-one meetings. A simultaneous Webcast will be available at

For more information on the Roth conference, please visit the conference website at or call the conference desk at 800-678-9147. For media inquiries and press credentials only call 949-720-5700.

About Roth Capital Partners, LLC

With corporate headquarters in Newport Beach, California and offices in strategic locations in the Western United States and Shanghai, China, Roth Capital Partners, LLC is a full service investment bank serving corporate and institutional clients throughout the world. Offering a wide array of investment banking services including: initial public offerings, follow-ons, PIPEs, private placements, mergers and acquisitions, investment research, and institutional sales and trading, the firm is perhaps best known for finding, funding and fostering the growth of emerging companies. It is a member of the Financial Industry Regulatory Authority, Inc. ("FINRA"), and the Securities Investor Protection Corporation (SIPC). Visit the Roth Capital Partners website at

About AspenBio Pharma, Inc.

AspenBio Pharma is an emerging bio-pharmaceutical company dedicated to the discovery; development, manufacture, and marketing of novel proprietary products, including those that enhance the reproductive efficiency of animals and that have large worldwide market potential. The company was originally formed to produce purified proteins for diagnostic applications and has become a leading supplier of human hormones to many of the nation's largest medical diagnostic companies and research institutions. The company has successfully leveraged this foundational science and technology expertise to rapidly develop an enviable late-stage pipeline of several novel reproduction hormone analogs for wide-ranging therapeutic use initially in bovine and equine species. AspenBio Pharma continues to advance the development and testing of its two first-generation blood-based human diagnostic tests designed to rapidly help diagnose or rule out appendicitis in patients complaining of abdominal pain. For more information, go to

Investor Relations:

Liolios Group, Inc.

Ron Both

Tel 949-574-3860

SOURCE AspenBio Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. AspenBio Pharma Closes $18.2 Million Private Placement of Common Stock
2. AspenBio Pharma Announces $18 Million Private Placement of Common Stock
3. AspenBio Pharma Pursues FDA 510(k) Application Pathway for Appendicitis Blood Test
4. AspenBio Pharma to Present at the Oppenheimer Best Ideas 1x1 Conference
5. AspenBio Pharma to Present the Edgewater Research Investor Conference
6. AspenBio Pharma to Present at the Roth Capital Partners New York Investor Conference
7. AspenBio Pharma Shares to Trade on the NASDAQ Capital Markets Exchange Under Symbol APPY
8. AspenBio Pharma Reports Second Quarter 2007 Results
9. Technology Transforms Market Research in Pharmaceutical Industry
10. Onyx Pharmaceuticals Announces Fourth Quarter and Full Year 2007 Financial Results Teleconference and Webcast
11. Assured Pharmacy Consolidates Portland, Oregon Pharmacy
Post Your Comments:
(Date:6/23/2016)... Md. , June 23, 2016 A person ... from the crime scene to track the criminal down. ... the U.S. Food and Drug Administration (FDA) uses DNA evidence ... Sound far-fetched? It,s not. The FDA ... sequencing to support investigations of foodborne illnesses. Put as simply ...
(Date:6/23/2016)... , June 23, 2016  The Prostate Cancer Foundation (PCF) is ... treatments and faster cures for prostate cancer. Members of the Class of 2016 ... countries. Read More About the Class of 2016 PCF ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... Supplyframe, ... of the Supplyframe Design Lab . Located in Pasadena, Calif., the Design ... of how hardware projects are designed, built and brought to market. , The ...
(Date:6/23/2016)... 23, 2016 Apellis Pharmaceuticals, Inc. today ... trials of its complement C3 inhibitor, APL-2. The ... ascending dose studies designed to assess the safety, ... injection in healthy adult volunteers. Forty ... a single dose (ranging from 45 to 1,440mg) ...
Breaking Biology Technology:
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/29/2016)... RATON, Florida , March 29, 2016 ... or the "Company") LegacyXChange "LEGX" and SelectaDNA/CSI Protect are ... DNA in ink used in a variety of writing ... theft. Buyers of originally created collectibles from athletes on ... through forensic analysis of the DNA. ...
(Date:3/22/2016)... India , March 22, 2016 /PRNewswire/ ... market research report "Electronic Sensors Market for Consumer ... Proximity, & Others), Application (Communication & IT, ... Geography - Global Forecast to 2022", published ... industry is expected to reach USD 26.76 ...
Breaking Biology News(10 mins):